Lipocine Company Profile (NASDAQ:LPCN)

Analyst Ratings

Consensus Ratings for Lipocine (NASDAQ:LPCN) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00 (64.84% upside)

Analysts' Ratings History for Lipocine (NASDAQ:LPCN)
Show:
DateFirmActionRatingPrice TargetActions
7/2/2016Canaccord GenuityReiterated RatingBuy$15.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/22/2015Roth CapitalInitiated CoverageBuy$36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/17/2015Evercore ISIInitiated CoverageBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/16/2015Evercore Partners Inc.Initiated CoverageBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Lipocine (NASDAQ:LPCN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/9/2016Q1($0.33)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q3($0.35)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015($0.20)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.35)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2015($0.35)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.58)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014($0.42)($0.55)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014($0.35)($0.41)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Lipocine (NASDAQ:LPCN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.34)($0.19)($0.27)
Q2 20162($0.38)($0.34)($0.36)
Q3 20162($0.34)($0.30)($0.32)
Q4 20162($0.41)($0.35)($0.38)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Lipocine (NASDAQ:LPCN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Lipocine (NASDAQ:LPCN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
9/30/2015John W HiguchiDirectorBuy5,000$12.68$63,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2015Mahesh V. PatelCEOBuy4,000$11.84$47,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Mahesh V PatelCEOBuy2,000$5.10$10,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Mahesh V PatelCEOBuy2,000$5.45$10,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Richard Dana OnoDirectorBuy4,000$5.14$20,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2014Mahesh V PatelCEOBuy2,000$5.06$10,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Mahesh V PatelCEOBuy2,000$5.05$10,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Stephen A HillDirectorBuy4,000$4.95$19,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Lipocine (NASDAQ:LPCN)
DateHeadline
07/25/16 05:09 PMLawsuit for Investors in shares of Lipocine Inc (US: LPCN) announced by Shareholders Foundation
07/25/16 10:40 AMIMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Lipocine Inc. and Reminds Investors with Losses to Contact the Firm - [Accesswire] - IRVINE, CA / ACCESSWIRE / July 25, 2016 / Khang & Khang LLP (the "Firm") announces that a class action lawsuit was filed against Lipocine Inc. ("Lipocine" or the "Company") ...
07/25/16 09:33 AMLawsuit for Investors in shares of Lipocine Inc (NASDAQ:LPCN) announced by Shareholders Foundation - GlobeNewswire (press release)
07/25/16 09:15 AMLawsuit for Investors in shares of Lipocine Inc (NASDAQ:LPCN) announced by Shareholders Foundation - [GlobeNewswire] - SAN DIEGO, July 25, 2016-- The Shareholders Foundation, Inc. announces that a lawsuit was filed in New Jersey on behalf of certain purchasers of shares of Lipocine Inc over alleged Securities Laws Violations ...
07/22/16 04:55 PMLipocine Inc. (NASDAQ:LPCN): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/22/16 04:21 PMSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lipocine Inc. of Class Action Lawsuit and Upcoming Deadline - LPCN - [Accesswire] - NEW YORK, NY / ACCESSWIRE / July 22, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against Lipocine Inc. ("Lipocine" or the"Company") (NASDAQ: LPCN), and ...
07/21/16 05:14 PMChecking in on Stock Volatility for: Lipocine Inc. (NASDAQ:LPCN) - Engelwood Daily
07/21/16 05:14 PMCohen Milstein Sellers & Toll PLLC Announces the Investigation of Lipocine, Inc. - Business Wire (press release)
07/21/16 05:14 PMBroker Outlook For Lipocine Inc (LPCN) - Fiscal Standard
07/21/16 01:48 PMCohen Milstein Sellers & Toll PLLC Announces the Investigation of Lipocine, Inc. - [Business Wire] - Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether Lipocine, Inc. and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10 and 20 of the Securities Exchange Act of 1934.
07/21/16 11:34 AMINVESTOR NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Lipocine Inc. and Reminds Investors with Losses to Contact the Firm - [Accesswire] - IRVINE, CA / ACCESSWIRE / July 21, 2016 / Khang & Khang LLP (the "Firm") announces that a class action lawsuit has been filed against Lipocine Inc. ("Lipocine" or the "Company") ...
07/21/16 09:30 AMThe Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Lipocine Inc. Investors and Encourages Investors to Contact the Firm - [Business Wire] - Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Lipocine Inc. securities between February 27, 2015 and June 28, 2016, inclusive .
07/20/16 09:15 AMSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Lipocine, Inc. (LPCN) and Lead Plaintiff Deadline August 30, 2016 - [Accesswire] - NEW YORK, NY / ACCESSWIRE / July 20, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Lipocine, Inc. ("Lipocine" or the "Company") ...
07/20/16 07:58 AMEarnings Focus and Crowd Sourced Sentiment Review for Lipocine Inc. (NASDAQ:LPCN) - TGP
07/20/16 07:58 AMLipocine Inc Realized Volatility Hits Extreme Level - CML News
07/19/16 05:07 PMINVESTOR ALERT: Brower Piven Encourages...
07/19/16 01:01 PMINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Lipocine Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit - [Business Wire] - The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Lipocine Inc.
07/19/16 11:04 AMLipocine Inc : Lundin Law PC Announces Securities Class Action Lawsuit Against Lipocine Inc. And Reminds Investors With Losses To Contact The Firm
07/18/16 06:18 PMIMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Lipocine Inc. And Reminds Investors With Losses To Contact The Firm - [Accesswire] - LOS ANGELES, CA / ACCESSWIRE / July 18, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Lipocine Inc. ("Lipocine" or the "Company") (Nasdaq: LPCN) concerning ...
07/18/16 05:20 PMSHAREHOLDER NOTICE: Rosen Law Firm Reminds Lipocine Inc. Investors of Important Deadline in Class Action Filed by Firm - LPCN - [Business Wire] - Rosen Law Firm, a global investor rights law firm, reminds purchasers of Lipocine Inc. securities from June 30, 2015 through June 28, 2016, inclusive of the important August 30, 2016 lead plaintiff deadline in the class action filed by the firm.
07/18/16 04:31 PM5:31 pm Lipocine approves restructuring, will reduce workforce by ~33% -
07/18/16 04:29 PMLIPOCINE INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities -
07/18/16 12:41 PMINVESTOR NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Lipocine Inc. and Encourages Investors with Losses to Contact the Firm - [Business Wire] - Goldberg Law PC announces that a class action lawsuit has been filed against Lipocine Inc. . Investors who purchased or otherwise acquired shares between June 30, 2015 and June 28, 2016 are encouraged to contact the firm in advance of the August 30, 2016 lead plaintiff motion deadline.
07/18/16 09:22 AMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors in Lipocine Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 30, 2016 - LPCN - [Accesswire] - NEW YORK, NY / ACCESSWIRE / July 18, 2016 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Lipocine Inc. ...
07/16/16 04:42 PMSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment Lipocine Inc. …
07/15/16 04:04 PMAnalyst Target and Average Rating Watch: Lipocine Inc. (NASDAQ:LPCN) - Press Telegraph
07/15/16 03:30 PMSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment Lipocine Inc. of Class Action Lawsuit and Upcoming Deadline - LPCN - [PR Newswire] - NEW YORK, July 15, 2016 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Lipocine Inc. ("Lipocine" or the "Company") (LPCN), and certain of the company's officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons other than Defendants who purchased or acquired Lipocine securities between June 30, 2015 and June 28, 2016, both dates inclusive (collectively, the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder. If you are a shareholder who purchased or otherwise acquired Lipocine securities during the Class Period, you have until August 30, 2016 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext.
07/15/16 11:44 AMIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Lipocine Inc. and Reminds Investors with Losses to Contact the Firm - [Accesswire] - IRVINE, CA / ACCESSWIRE / July 15, 2016 / Khang & Khang LLP (the "Firm") announces that a class action lawsuit has been filed against Lipocine Inc. ("Lipocine" or the "Company") ...
07/15/16 09:15 AMLipocine Inc. (NASDAQ:LPCN) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 04:30 PMIMPORTANT LIPOCINE, INC. SHAREHOLDER UPDATE: Wolf Haldenstein Adler Freeman & Herz LLP Reminds Investors that a Class Action Lawsuit with an Expanded Class Period has been Commenced on Behalf of Shareholders of Lipocine, Inc. - [Accesswire] - Lead Plaintiff Deadline is August 30, 2016 NEW YORK, NY / ACCESSWIRE / July 14, 2016 / Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States ...
07/14/16 08:35 AMHow Many Lipocine Inc (NASDAQ:LPCN)'s Analysts Are Bullish? - Consumer Eagle
07/14/16 08:35 AMTrading Performance and Target Watch for Lipocine Inc. (NASDAQ:LPCN) - Press Telegraph
07/13/16 12:10 PMSHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Lipocine Inc. and Reminds Investors with Losses to Contact the Firm - [Accesswire] - LOS ANGELES, CA / ACCESSWIRE / July 13, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Lipocine Inc. ("Lipocine" or the "Company") (NASDAQ: LPCN) concerning ...
07/13/16 09:15 AMSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action against Lipocine, Inc. (LPCN) and Lead Plaintiff Deadline August 30, 2016 - [Accesswire] - NEW YORK, NY / ACCESSWIRE / July 13, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Lipocine, Inc. ("Lipocine" or the "Company") ...
07/13/16 07:56 AMInvestor News: Lawsuit against Lipocine Inc (NASDAQ:LPCN) alleges Misleading Statements - GroundReport
07/12/16 09:49 AMINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Lipocine Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 30, 2016 -- LPCN - [Marketwired] - The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Lipocine Inc. between June 30, 2015 and June 28, 2016.......
07/12/16 09:24 AMInvestor News: Lawsuit against Lipocine Inc (NASDAQ:LPCN) alleges Misleading Statements
07/11/16 07:00 PMGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Lipocine, Inc. (LPCN) - [GlobeNewswire] - NEW YORK, July 11, 2016-- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Lipocine, Inc. in the United States District Court for the District of New Jersey on behalf ...
07/11/16 05:03 PMLipocine Lied About Testosterone Pill’s Chances, Investors Say
07/09/16 05:40 PMIMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit Against Lipocine Inc. and Reminds Investors With Losses to Contact the Firm - [Business Wire] - Khang & Khang LLP announces that a class action lawsuit has been filed against Lipocine Inc. . Investors who purchased or otherwise acquired shares between June 30, 2015 and June 28, 2016 inclusive , are encouraged to contact the Firm prior to the August 30, 2016 lead plaintiff motion deadline.
07/08/16 05:07 PMCan Lipocine Inc. (NASDAQ:LPCN) Improve on the Earnings Front? - Engelwood Daily
07/08/16 04:50 PMIMPORTANT LIPOCINE, INC. SHAREHOLDER ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Reminds Investors That a Class Action Lawsuit Has Been Commenced on Behalf of Shareholders of Lipocine, Inc. - [Accesswire] - Lead Plaintiff Deadline Is August 30, 2016 NEW YORK, NY / ACCESSWIRE / July 8, 2016 / Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States ...
07/08/16 10:01 AMSHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action Involving Lipocine Inc. and a Lead Plaintiff Deadline of August 30, 2016 - LPCN - [GlobeNewswire] - NEW YORK, July 08, 2016-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Lipocine ...
07/08/16 09:25 AMSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action against Lipocine, Inc. (LPCN) and Lead Plaintiff Deadline August 30, 2016 - [Accesswire] - NEW YORK, NY / ACCESSWIRE / July 8, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Lipocine, Inc. ("Lipocine" or the "Company") ...
07/08/16 07:53 AMCompany Stock Focus for Lipocine Inc. (NASDAQ:LPCN): Which Way Will Shares Head? - Press Telegraph
07/08/16 07:53 AMRyan & Maniskas, LLP Announces Class Action Lawsuit Against Lipocine Inc. - PR Newswire (press release)
07/07/16 08:15 PMIMPORTANT NOTICE TO SHAREHOLDERS: Brower Piven Notifies Shareholders of Securities Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Lipocine Inc. To Contact Brower Piven Before The Lead - [GlobeNewswire] - STEVENSON, Md., July 07, 2016-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court ...
07/07/16 06:35 PMRyan & Maniskas, LLP Announces Class Action Lawsuit Against Lipocine Inc. - [PR Newswire] - WAYNE, Pa., July 7, 2016 /PRNewswire/ -- Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in United States District Court for the District of New Jersey on behalf of purchasers of Lipocine Inc. ("Lipocine" or the "Company") (LPCN) between June 30, 2015 and June 28, 2016, inclusive (the "Class Period"). Lipocine shareholders may, no later than August 30, 2016, move the Court for appointment as a lead plaintiff of the Class. If you purchased shares of Lipocine and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/lpcn.
07/07/16 06:24 PMINVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Lipocine Inc. And Reminds Investors With Losses To Contact The Firm - [Business Wire] - Lundin Law PC announces a class action lawsuit has been filed against Lipocine Inc. concerning possible violations of federal securities laws between June 30, 2015 and June 28, 2016 .
07/07/16 05:01 PMLipocine Inc (LPCN) Current Analyst Ratings - Fiscal Standard

Social

About Lipocine

Lipocine logoLipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: LPCN
  • CUSIP:
Key Metrics:
  • Previous Close: $3.64
  • 50 Day Moving Average: $5.45
  • 200 Day Moving Average: $8.75
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $66.46M
  • Beta: 1.56
  • Current Year EPS Consensus Estimate: $-1.41 EPS
  • Next Year EPS Consensus Estimate: $-1.99 EPS
Additional Links:
Lipocine (NASDAQ:LPCN) Chart for Tuesday, July, 26, 2016